Next Article in Journal
Regulation of Fibroblast Cell Polarity by Src Tyrosine Kinase
Previous Article in Journal
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?
Open AccessArticle

A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats

1
Department of Virology, Institute of Experimental Medicine, 197376 Saint Petersburg, Russia
2
Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Zong Sheng Guo
Biomedicines 2021, 9(2), 133; https://doi.org/10.3390/biomedicines9020133
Received: 21 December 2020 / Revised: 26 January 2021 / Accepted: 27 January 2021 / Published: 1 February 2021
(This article belongs to the Section Immunology and Immunotherapy)
Influenza viruses remain a serious public health problem. Vaccination is the most effective way to prevent the disease; however, seasonal influenza vaccines demonstrate low or no effectiveness against antigenically drifted and newly emerged influenza viruses. Different strategies of eliciting immune responses against conserved parts of various influenza virus proteins are being developed worldwide. We constructed a universal live attenuated influenza vaccine (LAIV) candidate with enhanced breadth of protection by modifying H7N9 LAIV by incorporating four epitopes of M2 protein extracellular part into its hemagglutinin molecule. The new recombinant H7N9+4M2e vaccine induced anti-M2e antibody responses and demonstrated increased protection against heterosubtypic challenge viruses in direct and serum passive protection studies, compared to the classical H7N9 LAIV. The results of our study suggest that the H7N9+4M2e warrants further investigation in pre-clinical and phase 1 clinical trials. View Full-Text
Keywords: influenza; universal influenza vaccine; live attenuated influenza vaccine; M2e antigen; recombinant influenza virus; cross-protection; mouse model; CDC; ADCC; IgG influenza; universal influenza vaccine; live attenuated influenza vaccine; M2e antigen; recombinant influenza virus; cross-protection; mouse model; CDC; ADCC; IgG
Show Figures

Figure 1

MDPI and ACS Style

Mezhenskaya, D.; Isakova-Sivak, I.; Kotomina, T.; Matyushenko, V.; Kim, M.-C.; Bhatnagar, N.; Kim, K.-H.; Kang, S.-M.; Rudenko, L. A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats. Biomedicines 2021, 9, 133. https://doi.org/10.3390/biomedicines9020133

AMA Style

Mezhenskaya D, Isakova-Sivak I, Kotomina T, Matyushenko V, Kim M-C, Bhatnagar N, Kim K-H, Kang S-M, Rudenko L. A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats. Biomedicines. 2021; 9(2):133. https://doi.org/10.3390/biomedicines9020133

Chicago/Turabian Style

Mezhenskaya, Daria; Isakova-Sivak, Irina; Kotomina, Tatiana; Matyushenko, Victoria; Kim, Min-Chul; Bhatnagar, Noopur; Kim, Ki-Hye; Kang, Sang-Moo; Rudenko, Larisa. 2021. "A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats" Biomedicines 9, no. 2: 133. https://doi.org/10.3390/biomedicines9020133

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop